Partnering with patients to improve therapeutic outcomes: incretin-based therapy for type 2 diabetes (Q42171159)

17 October 2017

title

Partnering with patients to improve therapeutic outcomes: incretin-based therapy for type 2 diabetes (English)

1 reference

17 October 2017

1 reference

Daniel A Nadeau

1

1 reference

17 October 2017

language of work or name

English

0 references

publication date

1 May 2010

1 reference

17 October 2017

published in

Postgraduate Medicine

1 reference

17 October 2017

volume

122

1 reference

17 October 2017

issue

3

1 reference

17 October 2017

page(s)

7-15

1 reference

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

17 October 2017

cites work

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

Effects of intensive glucose lowering in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

Glucose control and vascular complications in veterans with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Card

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

Global and societal implications of the diabetes epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

Epidemiologic and economic consequences of the global epidemics of obesity and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

The UPS in diabetes and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

Type 2 diabetes mellitus: magnitude of the problem and failure to achieve glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

Insulin resistance: a proinflammatory state mediated by lipid-induced signaling dysfunction and involved in atherosclerotic plaque instability

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

Long-term weight loss from lifestyle intervention benefits blood pressure?: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

Treating diabetes and prediabetes by focusing on obesity management.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

A moderate-protein diet produces sustained weight loss and long-term changes in body composition and blood lipids in obese adults

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

Leisure-time physical activity patterns by weight control status: 1999-2002 NHANES.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

Current therapeutic options in type 2 diabetes mellitus: a practical approach

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

Use of thiazolidinediones and fracture risk

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

Thiazolidinedione use and bone loss in older diabetic adults

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for th

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICT

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

Preference for insulin delivery systems among current insulin users and nonusers.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

Patient satisfaction and costs associated with insulin administered by pen device or syringe during hospitalization

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

The Why WAIT program: improving clinical outcomes through weight management in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

Motivational interviewing improves weight loss in women with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

Exendin-4 improves the oral glucose tolerance in diabetic rats: pancreas regeneration, better function of pancreatic islets, or impaired glucose uptake?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

Exendin-4 protects beta-cells from interleukin-1 beta-induced apoptosis by interfering with the c-Jun NH2-terminal kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: analysis using claims, laboratory, and medical record data

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

Estimating the long-term cost-effectiveness of exenatide in the United States: an adjunctive treatment for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2137

21 January 2018

Identifiers

DOI

10.3810/PGM.2010.05.2137

1 reference

release_67cdw5krqng6zlhapqhdsfmxcy

17 October 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/67cdw5krqng6zlhapqhdsfmxcy

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference